R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

Inclusion Criteria

• •Pathologically confirmed diagnosis of CD20-positive diffuse large B-cell lymphoma
• •60\~80 years old
• •Ann Arbor stage I\~IV
• •ECOG physical score of 0\~2
• •Have not received previous treatment to lymphoma, including chemotherapy, radiotherapy, or biotherapy
• •Have at least one clinically measurable lesion: \>= 2cm under physical examination, or \>= 1.5cm under computed tomography (CT) or magnetic resonance (MR)
• •Life expectancy of \>= 3 months
• •Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase and total bilirubin \<= 2 × upper limit of normal (ULN)
• •Glomerular filtration rate (MDRD method) \>= 30ml/min
• •No abnormalities in blood coagulative function
• •Generally normal bone marrow function: while blood cell \>= 3,000/μL, absolute neutrophil count \>= 1,500/μL, hemoglobin \>= 100g/L, platelet \>= 75,000/μL
• •No evidence of active hepatitis B or C virus, or human immunodeficiency virus infection
• •Left ventricular ejection fraction (LVEF) \>= 45% measured by two dimensional echocardiography or multi-gated acquisition (MUGA) scan
• •Cardiac function of class I-II in New York Heart Association (NYHA) classification